Payment overview · 2025
General Payments
$439.60
25 reported records · 10 companies
Healthcare provider profile · identity verified
William C Sawyer, MD
Allopathic & Osteopathic Physicians|Family Medicine · SALUDA, SC · NPI 1841242146
Verified facts
What the public records show
CMS Open Payments records show William C Sawyer, MD received $439.60 in general payments during 2025 across 25 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $85.66 | 19.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.98 | 17.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.84 | 13.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.89 | 12.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.58 | 10.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $44.92 | 10.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.77 | 6.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.84 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.62 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.50 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.60 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $85.66 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.98 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.84 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $53.89 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.58 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $44.92 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.58 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.77 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 787 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 722 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 657 | 123 |
| Metoprolol Succinate | Metoprolol Succinate | 562 | 145 |
| Omeprazole | Omeprazole | 475 | 112 |
| Eliquis | Apixaban | 435 | 66 |
| Famotidine | Famotidine | 411 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 399 | 63 |
| Valsartan | Valsartan | 367 | 93 |
| Furosemide | Furosemide | 335 | 90 |
| Gabapentin | Gabapentin | 304 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 301 | 84 |
| Lisinopril | Lisinopril | 293 | 73 |
| Allopurinol | Allopurinol | 284 | 68 |
| Potassium Chloride | Potassium Chloride | 284 | 61 |
| Quetiapine Fumarate | Quetiapine Fumarate | 269 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 63 |
| Metformin Hcl Er | Metformin Hcl | 226 | 60 |
| Tramadol Hcl | Tramadol Hcl | 226 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 60 |
| Sertraline Hcl | Sertraline Hcl | 192 | 39 |
| Donepezil Hcl | Donepezil Hcl | 179 | 33 |
| Lorazepam | Lorazepam | 177 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 43 |
| Trazodone Hcl | Trazodone Hcl | 174 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 43 |
| Bumetanide | Bumetanide | 168 | 35 |
| Divalproex Sodium | Divalproex Sodium | 166 | 26 |
| Alprazolam | Alprazolam | 156 | 27 |
| Simvastatin | Simvastatin | 155 | 41 |
| Glimepiride | Glimepiride | 154 | 46 |
| Paroxetine Hcl | Paroxetine Hcl | 153 | 34 |
| Losartan Potassium | Losartan Potassium | 144 | 47 |
| Montelukast Sodium | Montelukast Sodium | 138 | 32 |
| Memantine Hcl | Memantine Hcl | 135 | 26 |
| Benazepril Hcl | Benazepril Hcl | 129 | 41 |
| Carvedilol | Carvedilol | 127 | 26 |
| Celecoxib | Celecoxib | 125 | 38 |
| Atenolol | Atenolol | 123 | 26 |
| Risperidone | Risperidone | 123 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 21 |
| Latanoprost | Latanoprost | 117 | 16 |
| Metformin Hcl | Metformin Hcl | 117 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 28 |
| Clonidine Hcl | Clonidine Hcl | 99 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 44 |
| Clonazepam | Clonazepam | 90 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 88 | 16 |
| Ozempic | Semaglutide | 81 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 35 |
| Alendronate Sodium | Alendronate Sodium | 79 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 12 |
| Ezetimibe | Ezetimibe | 77 | 25 |
| Spironolactone | Spironolactone | 76 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 29 |
| Ibuprofen | Ibuprofen | 70 | 31 |
| Meloxicam | Meloxicam | 66 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 18 |
| Prednisone | Prednisone | 65 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 11 |
| Methylprednisolone | Methylprednisolone | 64 | 53 |
| Levetiracetam | Levetiracetam | 63 | 11 |
| Buspirone Hcl | Buspirone Hcl | 61 | 18 |
| Pregabalin | Pregabalin | 61 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 16 |
| Azithromycin | Azithromycin | 57 | 49 |
| Irbesartan | Irbesartan | 57 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 56 | 23 |
| Cephalexin | Cephalexin | 55 | 39 |
| Temazepam | Temazepam | 52 | suppressed |
| Baclofen | Baclofen | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 38 |
| Humalog Kwikpen U-100 | Insulin Lispro | 50 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | suppressed |
| Levofloxacin | Levofloxacin | 49 | 42 |
| Amoxicillin | Amoxicillin | 48 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 14 |
| Januvia | Sitagliptin Phosphate | 47 | 12 |
| Terazosin Hcl | Terazosin Hcl | 47 | 14 |
| Warfarin Sodium | Warfarin Sodium | 45 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 24 |
| Chlorthalidone | Chlorthalidone | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Cefdinir | Cefdinir | 34 | 32 |
| Phenobarbital | Phenobarbital | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Finasteride | Finasteride | 33 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 16 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 17 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 28 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 15 |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 24 |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 17 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Letrozole | Letrozole | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 13 |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Nystatin | Nystatin | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | 12 |
| Colchicine | Colchicine | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.60 · 25 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AREXVY, FREESTYLE LIBRE 3, KISUNLA, Kerendia, Korlym, Ozempic, PENMENVY, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error